We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Arthrex Eclipse™ Shoulder Prosthesis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01790113
Recruitment Status : Terminated (Eclipse Shoulder System received 510(k) clearance on July 26, 2019.)
First Posted : February 13, 2013
Results First Posted : January 29, 2021
Last Update Posted : February 3, 2021
Information provided by (Responsible Party):
Arthrex, Inc.

Brief Summary:
A Prospective, Randomized, Multicenter Study comparing the Safety and Effectiveness of Arthrex's Eclipse™ Shoulder to the Univers™ II Shoulder Prosthesis in patients with a degenerative joint disease.

Condition or disease Intervention/treatment Phase
Osteoarthritis Device: Univers™ Device: Eclipse™ Total Shoulder Replacement Not Applicable

Detailed Description:
The purpose of this study is to demonstrate non-inferiority of the Arthrex Eclipse™ Shoulder Prosthesis to the Arthrex Univers™ II Shoulder Prosthesis for the treatment of degenerative joint disease in subjects who are candidates for total shoulder replacement. Non-inferiority in terms of safety and effectiveness will be measured by a 2 year composite clinical success (CCS) that requires functional improvement, radiographic success, absence of reoperations and revision, and lack of serious device-related adverse events.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 303 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Randomized, Multicenter Study Comparing the Safety and Effectiveness of Arthrex's Eclipse™ Shoulder Prothesis to the Univers™ II Shoulder Prosthesis in Patients With a Degenerative Joint Disease
Actual Study Start Date : February 4, 2013
Actual Primary Completion Date : June 7, 2019
Actual Study Completion Date : June 7, 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Univer™ II
Univers™ II Total Shoulder Replacement
Device: Univers™

Experimental: Eclipse™
Eclipse™ Total Shoulder Replacement
Device: Eclipse™ Total Shoulder Replacement

Primary Outcome Measures :
  1. Composite Clinical Success [ Time Frame: 2 year ]

    To be considered a success, the eclipse subject must meet the following composite clinical success criteria:

    1. An improvement in the Adjusted Constant Score (for pain, Function, and range of motion) from baseline (pre-op) to the 24 month time-point that is > or = to 10 and a final Adjusted Constant Score > or + to 54.
    2. Radiographic success at the Month 24 time-point which is defined as absence of clinically significant humeral radiolucency, humeral migration/subsidence (relative to 3 month time-point), glenoid migration/subsidence (relative to the 3 month time-point), device disassembly or fracture, and/or periprosthetic fracture, as described in the radiographic protocol.
    3. No reoperation, removal or modification of any study component up to the subject's completion of the study.
    4. No serious device-related complications up to the subject's completion of the study.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The subject is > 21 years of age
  • The subject has continued symptoms in target shoulder despite at least 3 months of other treatment modalities(e.g.: anti-inflammatory, physical therapy and steroid injections)
  • The subject has a diagnosis in the target shoulder of one or more of the following:

osteoarthritis, avascular necrosis, post-traumatic arthritis, or rheumatoid arthritis.

  • The subject presents with pain and functional impairment in the index shoulder, measured by an Adjusted Constant Score of ≤50. Note: The Adjusted Constant Score will be calculated from the raw Constant Score to establish patient eligibility.
  • The subject is willing to receive implantation of the Arthrex™ Shoulder Prosthesis or Univers™ II Shoulder Prosthesis.
  • The subject must be physically and mentally willing and able to comply with all study procedures (including follow-up visits and radiographic assessments) until the conclusion of the study.
  • The subject has been informed of the nature of the study and provided written consent as approved by the sites local Institutional Review Board or Ethic Review Board.

Exclusion Criteria:

  • The subject is likely a candidate for hemi-humeral arthroplasty (i.e.: Avascular Necrosis of the humeral head without glenoid involvement (Stages 0-3): Rotator Cuff Deficient Shoulder: Glenoid Bone deficiency/deformity that precludes glenoid replacement (Walch Type B2 or C) or Fractures of the Proximal Humerus, without Glenoid involvement.
  • The subject has immature bone as defined by the absence of cancellous bone patterning, a mature, thick cortex, and stress lines within the cancellous bone.
  • The subject has obvious defects in bone quality, such as cysts or lesions, in the humeral head of the target shoulder, as demonstrated by radiographic evaluation.
  • The subject has a target shoulder a rotator cuff that is not intact and not reconstructible.
  • The subject has Irreducible 3- and 4- part proximal humeral fractures of the target shoulder.
  • The subject has documented history of foreign-body sensitivity.
  • Subject with positive pregnancy test, or lactating, or intends to become pregnant during treatment period
  • The subject has history of Schizophrenia, Bipolar Disorder and/or Major Depressive Disorder as defined by DSM IV.
  • The subject is skeletally immature demonstrated radiographically by incomplete closure of proximal humeral epiphyses.
  • The subject is at high risk for poor healing or confounding outcomes [(i.e.: clinically significant renal, hepatic, cardiac hematologic disease or endocrine disease)]
  • The subject is on immune-stimulating or immunosuppressive agents
  • The subject has co-morbidity that reduces life expectancy < 36 month.
  • The subject seeking or receiving workman's compensation for shoulder injury,
  • The subject is > 350 lbs.
  • The subject engaged in heavy labor (e.g. repetitive lifting in the excess of more than 50 lbs.)
  • The subject has had surgery in the affected shoulder in the last 12 months (with the exception of diagnostic arthroscopy without reconstruction or repair procedures)
  • The subject is engaged in active sports participation. (e.g. weight lifting involving upper extremities or involved in contact sports)
  • The subject is taking medications known to potentially interfere with bone/soft tissue healing (e.g. steroids with the exception of topical and/or inhalers)
  • The subject is a prisoners or wards of the state
  • The subject has a history of alcohol and/or substance abuse as defined by DSM IV (Diagnostic and Statistical Manual Diploma in Social Medicine)
  • The subject has an active or chronic infection, either systemic or local.
  • The subject has pathologic fractures of the affected shoulder
  • The subject has acute trauma of the affected shoulder
  • The subject has osteoporosis defined as a bone density T score of < or = -2.5. (A screening Questionnaire for osteoporosis, SCORE (Simple Calculated Osteoporosis Risk Estimation) and MORES (Male Osteoporosis Risk Estimation Score), will be used to screen patients who require a DEXA (dual energy x-ray absorptiometry) bone mineral density measurement.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01790113

Layout table for location information
United States, Arizona
Banner Research
Sun City, Arizona, United States, 85351
United States, California
Orthopedics Stanford University
Redwood City, California, United States, 94063
United States, Colorado
Western Orthopaedics
Denver, Colorado, United States, 80218
United States, Illinois
Midwest Orthopaedics at Rush
Chicago, Illinois, United States, 60612
United States, Kentucky
Ellis and Badenhausen Orthopedics PSC
Louisville, Kentucky, United States, 40223
United States, Maryland
Medstar Health Research Institute
Hyattsville, Maryland, United States, 20782
Peninsula Orthopaedics Associates, P.A.
Salisbury, Maryland, United States, 21804
United States, Minnesota
Essentia Health Duluth
Duluth, Minnesota, United States, 55805
United States, New York
Excelsior Orthopedics
Amherst, New York, United States, 14226
SUNY Upstate Medical Universtiy
East Syracuse, New York, United States, 13057
United States, Ohio
Adena Health System
Chillicothe, Ohio, United States, 45601
OhioHealth Research Institute at Grant Medical Center
Columbus, Ohio, United States, 43215
United States, Oregon
Southern Oregon Orthopedics
Medford, Oregon, United States, 97504
United States, Pennsylvania
University Orthopedics
Altoona, Pennsylvania, United States, 16602
Rothman Institute
Philadelphia, Pennsylvania, United States, 19108
United States, South Carolina
Palmetto Health Orthopedics (formerly Providence Orthopedics Group, LLC_Moore Orthopedics)
Columbia, South Carolina, United States, 29203
Sponsors and Collaborators
Arthrex, Inc.
Layout table for investigator information
Study Director: Melissa Hirschberg Arthrex, Inc.
  Study Documents (Full-Text)

Documents provided by Arthrex, Inc.:
Layout table for additonal information
Responsible Party: Arthrex, Inc.
ClinicalTrials.gov Identifier: NCT01790113    
Other Study ID Numbers: Arthrex 003
First Posted: February 13, 2013    Key Record Dates
Results First Posted: January 29, 2021
Last Update Posted: February 3, 2021
Last Verified: October 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases